PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33938785-13 2021 Mechanistically, FK506 required ALK1 in hCFs as BMPR2 co-receptor to reduce TGFbeta1-induced proliferation and collagen production. Tacrolimus 17-22 transforming growth factor beta 1 Homo sapiens 76-84 27128949-0 2016 Tacrolimus Modulates TGF-beta Signaling to Induce Epithelial-Mesenchymal Transition in Human Renal Proximal Tubule Epithelial Cells. Tacrolimus 0-10 transforming growth factor beta 1 Homo sapiens 21-29 33206751-8 2020 Moreover, the drug combination of mycophenolate mofetil and tacrolimus greatly reduced the expression levels of serum TGF-beta1 and cystatin C. Tacrolimus 60-70 transforming growth factor beta 1 Homo sapiens 118-127 30633591-8 2019 The levels of the relative cytokines (TGF-beta and IL-10) in FK506 group are down-regulated compared to the control group. Tacrolimus 61-66 transforming growth factor beta 1 Homo sapiens 38-46 27372923-3 2016 Therefore, the aim of this study was to investigate the expression profile of TGFbeta isoforms, their receptors, and TGFbeta-related genes in human retinal pigment epithelial cells (RPE) after tacrolimus (FK-506) treatment in the presence or absence of lipopolysaccharide (LPS)-induced inflammation. Tacrolimus 193-203 transforming growth factor beta 1 Homo sapiens 78-85 27372923-3 2016 Therefore, the aim of this study was to investigate the expression profile of TGFbeta isoforms, their receptors, and TGFbeta-related genes in human retinal pigment epithelial cells (RPE) after tacrolimus (FK-506) treatment in the presence or absence of lipopolysaccharide (LPS)-induced inflammation. Tacrolimus 205-211 transforming growth factor beta 1 Homo sapiens 117-124 27372923-5 2016 RESULTS: Analysis using oligonucleotide microarrays revealed 20 statistically significant differentially expressed TGFbeta-related genes after LPS treatment in relation to control cells, and after tacrolimus and LPS treatment in relation to LPS-treated cells. Tacrolimus 197-207 transforming growth factor beta 1 Homo sapiens 115-122 28901186-11 2017 Analysis of recipient peripheral blood revealed that transforming growth factor beta1 (TGFbeta1) was significantly increased in the rADSC-IR-FK506 group. Tacrolimus 141-146 transforming growth factor beta 1 Homo sapiens 53-85 28901186-11 2017 Analysis of recipient peripheral blood revealed that transforming growth factor beta1 (TGFbeta1) was significantly increased in the rADSC-IR-FK506 group. Tacrolimus 141-146 transforming growth factor beta 1 Homo sapiens 87-95 28060893-9 2017 On the other hand, pro-fibrotic stimuli being detrimental to renal function were induced by tacrolimus like the transforming growth factor beta 1 (TGFB1), endothelin 1 (EDN1), or type IV collagen alpha 1 (COL4A1). Tacrolimus 92-102 transforming growth factor beta 1 Homo sapiens 112-145 28060893-9 2017 On the other hand, pro-fibrotic stimuli being detrimental to renal function were induced by tacrolimus like the transforming growth factor beta 1 (TGFB1), endothelin 1 (EDN1), or type IV collagen alpha 1 (COL4A1). Tacrolimus 92-102 transforming growth factor beta 1 Homo sapiens 147-152 27372923-0 2016 Transforming growth factor beta-related genes in human retinal pigment epithelial cells after tacrolimus treatment. Tacrolimus 94-104 transforming growth factor beta 1 Homo sapiens 0-31 27128949-4 2016 FK506 effects on TGF-beta mRNA were assessed by RT PCR and TGF-beta secretion was measured by ELISA. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 17-25 27128949-8 2016 Additionally, the study demonstrates that FK506 activation of the TGF-beta/ SMAD pathways is an essential step in the EMT process. Tacrolimus 42-47 transforming growth factor beta 1 Homo sapiens 66-74 23301526-0 2014 Tacrolimus abrogates TGF-beta1-induced type I collagen production in normal human fibroblasts through suppressing p38MAPK signalling pathway: implications on treatment of chronic atopic dermatitis lesions. Tacrolimus 0-10 transforming growth factor beta 1 Homo sapiens 21-30 23301526-13 2014 The increase in phosphorylated p38 mitogen-activated protein kinase (p38MAPK) expression stimulated by TGF-beta1 was down-regulated by tacrolimus. Tacrolimus 135-145 transforming growth factor beta 1 Homo sapiens 103-112 23301526-15 2014 CONCLUSIONS: The present results demonstrated that tacrolimus significantly inhibited physiological functions of fibroblasts enhanced by TGF-beta1 in vitro. Tacrolimus 51-61 transforming growth factor beta 1 Homo sapiens 137-146 25964218-6 2015 CONCLUSION: Low serum TGF-beta and high IL-10 levels at post-transplantation month 6 might have a positive effect on graft survival in living donor kidney recipients on tacrolimus-based immunosuppressive treatment. Tacrolimus 169-179 transforming growth factor beta 1 Homo sapiens 22-30 24816588-0 2014 Tacrolimus increases Nox4 expression in human renal fibroblasts and induces fibrosis-related genes by aberrant TGF-beta receptor signalling. Tacrolimus 0-10 transforming growth factor beta 1 Homo sapiens 111-119 24816588-3 2014 In the human renal fibroblast cell line TK-173, the macrolide calcineurin inhibitor tacrolimus (FK-506) induced TGF-beta-like effects, manifested by increased expression of NAD(P)H-oxidase 4 (Nox4), transgelin, tropomyosin 1, and procollagen alpha1(V) mRNA after three days. Tacrolimus 84-94 transforming growth factor beta 1 Homo sapiens 112-120 24816588-3 2014 In the human renal fibroblast cell line TK-173, the macrolide calcineurin inhibitor tacrolimus (FK-506) induced TGF-beta-like effects, manifested by increased expression of NAD(P)H-oxidase 4 (Nox4), transgelin, tropomyosin 1, and procollagen alpha1(V) mRNA after three days. Tacrolimus 96-102 transforming growth factor beta 1 Homo sapiens 112-120 24816588-6 2014 The effects were independent of extracellular TGF-beta as confirmed by the use of neutralizing antibodies, and thus most likely caused by aberrant TGF-beta receptor signaling, where binding of tacrolimus to the regulatory FKBP12 protein results in a "leaky" TGF-beta receptor. Tacrolimus 193-203 transforming growth factor beta 1 Homo sapiens 147-155 24816588-6 2014 The effects were independent of extracellular TGF-beta as confirmed by the use of neutralizing antibodies, and thus most likely caused by aberrant TGF-beta receptor signaling, where binding of tacrolimus to the regulatory FKBP12 protein results in a "leaky" TGF-beta receptor. Tacrolimus 193-203 transforming growth factor beta 1 Homo sapiens 147-155 23301526-4 2014 Tacrolimus (FK506) ointment has been reported to be effective for treating AD as well as some TGF-beta1-induced fibrotic diseases. Tacrolimus 0-10 transforming growth factor beta 1 Homo sapiens 94-103 23301526-4 2014 Tacrolimus (FK506) ointment has been reported to be effective for treating AD as well as some TGF-beta1-induced fibrotic diseases. Tacrolimus 12-17 transforming growth factor beta 1 Homo sapiens 94-103 23301526-5 2014 OBJECTIVES: To evaluate the effect of tacrolimus on TGF-beta1-stimulated cultured normal human dermal fibroblasts and explore the potential signalling pathways involved. Tacrolimus 38-48 transforming growth factor beta 1 Homo sapiens 52-61 23301526-9 2014 RESULTS: Our results revealed that the increased expressions of transforming growth factor-beta receptor I (TGF-betaRI) and TGF-betaRII in TGF-beta1-treated fibroblasts were suppressed by tacrolimus treatment. Tacrolimus 188-198 transforming growth factor beta 1 Homo sapiens 139-148 23301526-10 2014 In addition, tacrolimus significantly inhibited fibroblast proliferation enhanced by TGF-beta1. Tacrolimus 13-23 transforming growth factor beta 1 Homo sapiens 85-94 23301526-11 2014 TGF-beta1 increased type I collagen production, and this enhancing effect was suppressed by tacrolimus. Tacrolimus 92-102 transforming growth factor beta 1 Homo sapiens 0-9 23301526-12 2014 The down-regulation of MMP-1 and up-regulation of TIMP-1 induced by TGF-beta1 were reversed by tacrolimus. Tacrolimus 95-105 transforming growth factor beta 1 Homo sapiens 68-77 22743729-12 2012 In heart recipients, TGF-beta genetic polymorphisms were associated with tacrolimus-induced nephrotoxicity. Tacrolimus 73-83 transforming growth factor beta 1 Homo sapiens 21-29 22540338-0 2012 FK506 inhibits the enhancing effects of transforming growth factor (TGF)-beta1 on collagen expression and TGF-beta/Smad signalling in keloid fibroblasts: implication for new therapeutic approach. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 40-78 22540338-0 2012 FK506 inhibits the enhancing effects of transforming growth factor (TGF)-beta1 on collagen expression and TGF-beta/Smad signalling in keloid fibroblasts: implication for new therapeutic approach. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 106-114 22540338-4 2012 As tacrolimus (FK506) has been reported to inhibit the effects of TGF-beta1 on cultured fibroblasts, we hypothesized that FK506 may be useful in treating keloids. Tacrolimus 3-13 transforming growth factor beta 1 Homo sapiens 66-75 22540338-4 2012 As tacrolimus (FK506) has been reported to inhibit the effects of TGF-beta1 on cultured fibroblasts, we hypothesized that FK506 may be useful in treating keloids. Tacrolimus 15-20 transforming growth factor beta 1 Homo sapiens 66-75 22540338-4 2012 As tacrolimus (FK506) has been reported to inhibit the effects of TGF-beta1 on cultured fibroblasts, we hypothesized that FK506 may be useful in treating keloids. Tacrolimus 122-127 transforming growth factor beta 1 Homo sapiens 66-75 22540338-5 2012 OBJECTIVES: To explore the effects of FK506 on TGF-beta1-stimulated keloid fibroblasts (KFs) in terms of proliferation, migration and collagen production and to investigate the regulatory pathways involved. Tacrolimus 38-43 transforming growth factor beta 1 Homo sapiens 47-56 22540338-9 2012 FK506 markedly inhibited KF proliferation, migration and collagen production enhanced by TGF-beta1. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 89-98 22540338-10 2012 The increase in TGF-beta receptor I and II expression in TGF-beta1-treated KFs was suppressed by FK506 treatment. Tacrolimus 97-102 transforming growth factor beta 1 Homo sapiens 16-24 22540338-10 2012 The increase in TGF-beta receptor I and II expression in TGF-beta1-treated KFs was suppressed by FK506 treatment. Tacrolimus 97-102 transforming growth factor beta 1 Homo sapiens 57-66 22540338-11 2012 TGF-beta1 increased the phosphorylation of Smad2/3 and Smad4 in KFs, and this enhancing effect was abrogated by FK506. Tacrolimus 112-117 transforming growth factor beta 1 Homo sapiens 0-9 22540338-12 2012 In addition, FK506 significantly increased the expression of Smad7 which was suppressed by TGF-beta1 treatment. Tacrolimus 13-18 transforming growth factor beta 1 Homo sapiens 91-100 22540338-13 2012 CONCLUSIONS: Our results demonstrate that FK506 effectively blocks the TGF-beta/Smad signalling pathway in KFs by downregulation of TGF-beta receptors and suggest that FK506 may be included in the armamentarium for treating keloids. Tacrolimus 42-47 transforming growth factor beta 1 Homo sapiens 71-79 22540338-13 2012 CONCLUSIONS: Our results demonstrate that FK506 effectively blocks the TGF-beta/Smad signalling pathway in KFs by downregulation of TGF-beta receptors and suggest that FK506 may be included in the armamentarium for treating keloids. Tacrolimus 42-47 transforming growth factor beta 1 Homo sapiens 132-140 22540338-13 2012 CONCLUSIONS: Our results demonstrate that FK506 effectively blocks the TGF-beta/Smad signalling pathway in KFs by downregulation of TGF-beta receptors and suggest that FK506 may be included in the armamentarium for treating keloids. Tacrolimus 168-173 transforming growth factor beta 1 Homo sapiens 71-79 22540338-13 2012 CONCLUSIONS: Our results demonstrate that FK506 effectively blocks the TGF-beta/Smad signalling pathway in KFs by downregulation of TGF-beta receptors and suggest that FK506 may be included in the armamentarium for treating keloids. Tacrolimus 168-173 transforming growth factor beta 1 Homo sapiens 132-140 22743729-14 2012 CONCLUSIONS: Limited evidence suggests that variation in genes involved in pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics (TGF-beta, CYP2C8, ACE, CCR5) of tacrolimus may impact a transplant recipients" risk to develop tacrolimus-induced nephrotoxicity across different transplant organ groups. Tacrolimus 165-175 transforming growth factor beta 1 Homo sapiens 133-141 22743729-14 2012 CONCLUSIONS: Limited evidence suggests that variation in genes involved in pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics (TGF-beta, CYP2C8, ACE, CCR5) of tacrolimus may impact a transplant recipients" risk to develop tacrolimus-induced nephrotoxicity across different transplant organ groups. Tacrolimus 228-238 transforming growth factor beta 1 Homo sapiens 133-141 21310938-0 2011 Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Tacrolimus 17-22 transforming growth factor beta 1 Homo sapiens 102-134 21310938-11 2011 Here, we find that the immunosuppressor FK506 increases the protein and mRNA expression of ENG and ALK1 in cultured endothelial cells and enhances the TGF-beta1/ALK1 signaling pathway and endothelial cell functions like tubulogenesis and migration. Tacrolimus 40-45 transforming growth factor beta 1 Homo sapiens 151-160 18355347-6 2008 RESULTS: The level of TGF-beta1 gene expression was insignificantly lower in the CsA-treated group compared with the tacrolimus group, and significantly lower in the group with GO compared with patients without GO. Tacrolimus 117-127 transforming growth factor beta 1 Homo sapiens 22-31 18342291-1 2008 BACKGROUND: Gingival crevicular fluid (GCF) levels of transforming growth factor-beta(1) (TGF-beta(1)) have been previously investigated in relation to the pathogenesis of cyclosporine-A (CsA)-induced gingival overgrowth (GO) but no clinical data are available regarding the GCF levels of TGF-beta(1) in patients treated with tacrolimus (Tac). Tacrolimus 326-336 transforming growth factor beta 1 Homo sapiens 54-88 18342291-1 2008 BACKGROUND: Gingival crevicular fluid (GCF) levels of transforming growth factor-beta(1) (TGF-beta(1)) have been previously investigated in relation to the pathogenesis of cyclosporine-A (CsA)-induced gingival overgrowth (GO) but no clinical data are available regarding the GCF levels of TGF-beta(1) in patients treated with tacrolimus (Tac). Tacrolimus 326-336 transforming growth factor beta 1 Homo sapiens 90-101 18349138-0 2008 FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 19-50 18349138-12 2008 We also demonstrate that FK506 activates the TGF-beta signal in VSMCs and that, through this mechanism, it stimulates cell proliferation. Tacrolimus 25-30 transforming growth factor beta 1 Homo sapiens 45-53 18492692-15 2008 FK506 removed FKBP12 from its binding to the TGF-beta-receptor. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 45-53 18492692-17 2008 CONCLUSIONS: Our study shows that most chronic lymphocytic leukemia cells escape the homeostatic control of TGF-beta and that FK506 restores the TGF-beta signal in a proportion of non-responsive samples. Tacrolimus 126-131 transforming growth factor beta 1 Homo sapiens 145-153 18492692-18 2008 We demonstrated that FK506 activates TGF-beta receptor I kinase activity in chronic lymphocytic leukemia, which transduces apoptosis by a mitochondrial-dependent pathway. Tacrolimus 21-26 transforming growth factor beta 1 Homo sapiens 37-45 19604038-6 2010 Addition of FK506 increased endogenous transforming growth factor 2 (TGF) beta1 expression on both mRNA and protein level. Tacrolimus 12-17 transforming growth factor beta 1 Homo sapiens 39-79 19604038-7 2010 The effect of FK506 on chondrogenic markers was abolished by addition of anti-TGFbeta1 antibody, indicating that the endogenous TGFbeta1 was necessary to increase chondrogenic marker expression. Tacrolimus 14-19 transforming growth factor beta 1 Homo sapiens 78-86 19604038-7 2010 The effect of FK506 on chondrogenic markers was abolished by addition of anti-TGFbeta1 antibody, indicating that the endogenous TGFbeta1 was necessary to increase chondrogenic marker expression. Tacrolimus 14-19 transforming growth factor beta 1 Homo sapiens 128-136 19604038-9 2010 In conclusion, inhibition of Cn activity by FK506 increases the expression of chondrogenic markers via endogenous TGFbeta1 production in human articular chondrocytes. Tacrolimus 44-49 transforming growth factor beta 1 Homo sapiens 114-122 18589121-5 2008 Tacrolimus did not affect COL-I, COL-III, or MMP gene expression, while LH2b and TGF-beta1 tended to be down-regulated after 1 mumol/L FK506. Tacrolimus 135-140 transforming growth factor beta 1 Homo sapiens 81-90 18355347-7 2008 In tacrolimus- and CsA-treated patients, but not in patients with GO, the level of TGF-beta1 gene expression was associated with functional phenotypes of TGF-beta1. Tacrolimus 3-13 transforming growth factor beta 1 Homo sapiens 83-92 18355347-7 2008 In tacrolimus- and CsA-treated patients, but not in patients with GO, the level of TGF-beta1 gene expression was associated with functional phenotypes of TGF-beta1. Tacrolimus 3-13 transforming growth factor beta 1 Homo sapiens 154-163 17292639-6 2007 Additionally, FK506 further enhanced chondrogenesis of synovial stromal cells (SSCs) induced by BMP2 and TGFbeta(1), also in a dose-dependent manner. Tacrolimus 14-19 transforming growth factor beta 1 Homo sapiens 105-115 16671880-4 2006 The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO. Tacrolimus 158-168 transforming growth factor beta 1 Homo sapiens 43-75 29539165-4 2006 The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO. Tacrolimus 158-168 transforming growth factor beta 1 Homo sapiens 43-75 29539165-4 2006 The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO. Tacrolimus 158-168 transforming growth factor beta 1 Homo sapiens 77-86 29539165-8 2006 TGF-beta1 plasma levels were estimated in 60 CsA- and 30 tacrolimus-treated patients. Tacrolimus 57-67 transforming growth factor beta 1 Homo sapiens 0-9 16773453-9 2006 Tacrolimus enhanced the production of TGF-beta, while hydrocortisone did not. Tacrolimus 0-10 transforming growth factor beta 1 Homo sapiens 38-46 16773453-10 2006 Restoration of TGF-beta-producing Treg cells may represent another important pharmacodynamic effect of tacrolimus on AD. Tacrolimus 103-113 transforming growth factor beta 1 Homo sapiens 15-23 16671880-4 2006 The aims of this study were to investigate transforming growth factor-beta1 (TGF-beta1) gene polymorphisms in renal transplant recipients treated with CsA or tacrolimus and to establish an association between these polymorphisms and TGF-beta1 plasma concentration and the incidence of GO. Tacrolimus 158-168 transforming growth factor beta 1 Homo sapiens 77-86 16671880-8 2006 TGF-beta1 plasma levels were estimated in 60 CsA- and 30 tacrolimus-treated patients. Tacrolimus 57-67 transforming growth factor beta 1 Homo sapiens 0-9 16507844-6 2006 FK506 inhibited TGF-beta-induced collagen synthesis, and suppressed the expression of TGF-beta type I receptor (TbetaR-I) in TIG-3-20 cells. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 16-24 16458528-4 2006 Here, we assessed the effect of FK506 on the expression of TGF-beta1, TbetaR-I, TbetaR-II, fibronectin (FN) and plasminogen activator inhibitor type-1 (PAI-1) in MCs. Tacrolimus 32-37 transforming growth factor beta 1 Homo sapiens 59-68 16458528-7 2006 Compared to untreated controls, FK506 stimulated TGF-beta1 mRNA (maximum at 8 h, 100 ng/mL: 2.13+/-0.15-fold, P<0.005) and protein expression (maximum at 96 h, 100 ng/mL: 1.96+/-0.29-fold, P<0.005). Tacrolimus 32-37 transforming growth factor beta 1 Homo sapiens 49-58 16458528-10 2006 These results indicate that, comparable to CsA, FK506 induced glomerulosclerosis is also due to a direct effect on mesangial matrix production, which is at least in part mediated via up-regulation of TGF-beta1 expression. Tacrolimus 48-53 transforming growth factor beta 1 Homo sapiens 200-209 15377358-0 2004 FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Tacrolimus 0-5 transforming growth factor beta 1 Homo sapiens 32-63 15716327-4 2005 In Jurkat T cells, the TGF-beta1 promoter was activated by calcineurin and NFATc and inhibited by CsA and FK506. Tacrolimus 106-111 transforming growth factor beta 1 Homo sapiens 23-32 15716327-7 2005 However, pretreatment of fresh lymphocytes with CsA or FK506 during primary TCR stimulation reduced their production of TGF-beta1 during secondary TCR activation. Tacrolimus 55-60 transforming growth factor beta 1 Homo sapiens 120-129 15716327-10 2005 Our results indicate that CsA and FK506 are not general inducers of TGF-beta1 biosynthesis but can cause different effects on TGF-beta1 depending on the cell type and concentrations used. Tacrolimus 34-39 transforming growth factor beta 1 Homo sapiens 68-77 15716327-10 2005 Our results indicate that CsA and FK506 are not general inducers of TGF-beta1 biosynthesis but can cause different effects on TGF-beta1 depending on the cell type and concentrations used. Tacrolimus 34-39 transforming growth factor beta 1 Homo sapiens 126-135 15818662-5 2005 RESULTS: FK-506 did not affect the basal expression of type I procollagen protein or alpha2(I) collagen mRNA, but it significantly reduced the TGFbeta1-induced expression of type I procollagen protein and alpha2(I) collagen mRNA in normal fibroblasts. Tacrolimus 9-15 transforming growth factor beta 1 Homo sapiens 143-151 15694998-8 2005 The TGFbeta1 high-producer genotype had worse CrCl than intermediate and low producers at every time point, despite similar pretransplant CrCl (pretransplant = 120 +/- 53 vs 118 +/- 55 ml/mn/1.73 m2 [p = 0.8], 1 year = 92 +/- 38 vs 113 +/- 30 ml/mn/1.73 m2 [p = 0.03]) and similar tacrolimus levels. Tacrolimus 281-291 transforming growth factor beta 1 Homo sapiens 4-12 15377358-4 2004 OBJECTIVES: To investigate the direct effects of FK506 on KCs in terms of TGF-beta and inducible NOS (iNOS), and to explore the interactions between TGF-beta and iNOS in the KC system. Tacrolimus 49-54 transforming growth factor beta 1 Homo sapiens 74-82 15377358-6 2004 The changes in the KC system induced by FK506 were documented in terms of TGF-beta and iNOS using enzyme-linked immunosorbent assay and Western blotting techniques, respectively. Tacrolimus 40-45 transforming growth factor beta 1 Homo sapiens 74-82 15377358-9 2004 RESULTS: Our results showed that the release of TGF-beta was upregulated in FK506-treated KCs, particularly in the presence of TNF-alpha, while the expression of iNOS was downregulated. Tacrolimus 76-81 transforming growth factor beta 1 Homo sapiens 48-56 15377358-11 2004 However, the addition of TNF-alpha did not further downregulate the expression of iNOS protein, suggesting that FK506 may regulate TGF-beta and iNOS through different pathways. Tacrolimus 112-117 transforming growth factor beta 1 Homo sapiens 131-139 7545487-3 1995 In contrast, both CsA and FK506 enhanced transforming growth factor beta (TGF beta) and IL-1 beta mRNA expression. Tacrolimus 26-31 transforming growth factor beta 1 Homo sapiens 41-72 12646197-0 2003 The immunosuppressive agent tacrolimus induces p21WAF/CIP1WAF1/CIP1 via TGF-beta secretion. Tacrolimus 28-38 transforming growth factor beta 1 Homo sapiens 72-80 12646197-9 2003 The induction of p21WAF/CIP1 expression by tacrolimus was dependent on TGF-beta since a neutralizing anti-TGF-beta antibody inhibited induction of p21WAF/CIP1in A-549 cells. Tacrolimus 43-53 transforming growth factor beta 1 Homo sapiens 71-79 12646197-9 2003 The induction of p21WAF/CIP1 expression by tacrolimus was dependent on TGF-beta since a neutralizing anti-TGF-beta antibody inhibited induction of p21WAF/CIP1in A-549 cells. Tacrolimus 43-53 transforming growth factor beta 1 Homo sapiens 106-114 12427154-0 2002 Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Tacrolimus 74-84 transforming growth factor beta 1 Homo sapiens 14-22 11849412-16 2002 In particular, the use of cyclosporine compared to tacrolimus was associated with a tenfold increase in TGF-beta mRNA (TGF-beta mRNA at 6 months, CsA vs. Tac, 3 +/- 0.3 vs. 2 +/- 0.3 log copies, P < 0.05), interstitial fibrosis (Vvi at 6 months, CsA vs. Tac, 33 +/- 4% vs. 24 +/- 2%, P < 0.05). Tacrolimus 51-61 transforming growth factor beta 1 Homo sapiens 104-112 11849412-16 2002 In particular, the use of cyclosporine compared to tacrolimus was associated with a tenfold increase in TGF-beta mRNA (TGF-beta mRNA at 6 months, CsA vs. Tac, 3 +/- 0.3 vs. 2 +/- 0.3 log copies, P < 0.05), interstitial fibrosis (Vvi at 6 months, CsA vs. Tac, 33 +/- 4% vs. 24 +/- 2%, P < 0.05). Tacrolimus 51-61 transforming growth factor beta 1 Homo sapiens 119-127 10972232-2 2000 The mechanism of action of cyclosporine and tacrolimus has been explained on the basis of their inhibition of interleukin-2 (IL-2), and induction of transforming growth factor-beta (TGF-beta). Tacrolimus 44-54 transforming growth factor beta 1 Homo sapiens 149-180 10972232-2 2000 The mechanism of action of cyclosporine and tacrolimus has been explained on the basis of their inhibition of interleukin-2 (IL-2), and induction of transforming growth factor-beta (TGF-beta). Tacrolimus 44-54 transforming growth factor beta 1 Homo sapiens 182-190 10972232-5 2000 RESULTS: In this study, we report that rapamycin in combination with either tacrolimus or cyclosporine significantly inhibited the lymphocyte proliferation, IL-2 expression, and induced TGF-beta, compared with these drugs alone. Tacrolimus 76-86 transforming growth factor beta 1 Homo sapiens 186-194 11112017-4 2000 The current study was designed to measure the expression of TGF-beta in renal transplant biopsies from patients immunosuppressed with either CyA or tacrolimus. Tacrolimus 148-158 transforming growth factor beta 1 Homo sapiens 60-68 9715421-3 1998 Using the same model, we examined the effect of FK506 on the expression of hepatocyte growth factor (HGF) and transforming growth factor-beta 1 (TGF-beta 1) and found no changes in HGF and TGF-beta 1 mRNA expression in the liver or in the HGF protein concentration in plasma. Tacrolimus 48-53 transforming growth factor beta 1 Homo sapiens 110-143 9715421-3 1998 Using the same model, we examined the effect of FK506 on the expression of hepatocyte growth factor (HGF) and transforming growth factor-beta 1 (TGF-beta 1) and found no changes in HGF and TGF-beta 1 mRNA expression in the liver or in the HGF protein concentration in plasma. Tacrolimus 48-53 transforming growth factor beta 1 Homo sapiens 145-155 12352326-7 2002 At baseline, in cyclosporine-and tacrolimus-treated patients, p22 and TGF-beta mRNA were similarly increased in comparison with normotensive healthy controls (0.90 +/- 0.05 d.u. Tacrolimus 33-43 transforming growth factor beta 1 Homo sapiens 70-78 10755567-0 2000 TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Tacrolimus 96-106 transforming growth factor beta 1 Homo sapiens 0-8 10755567-4 2000 The current study was designed to measure the expression of TGF-beta(b) in renal transplant biopsy specimens from patients undergoing immunosuppressive therapy with either CsA or tacrolimus (FK506). Tacrolimus 179-189 transforming growth factor beta 1 Homo sapiens 60-68 10755567-4 2000 The current study was designed to measure the expression of TGF-beta(b) in renal transplant biopsy specimens from patients undergoing immunosuppressive therapy with either CsA or tacrolimus (FK506). Tacrolimus 191-196 transforming growth factor beta 1 Homo sapiens 60-68 10480422-0 1999 Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. Tacrolimus 73-83 transforming growth factor beta 1 Homo sapiens 16-24 10480422-3 1999 To determine whether tacrolimus (FK506) similarly increases TGFbeta1 we have measured TGFbeta levels in blood samples from liver graft recipients who were of known TGFbeta1-responder status. Tacrolimus 33-38 transforming growth factor beta 1 Homo sapiens 60-68 10480422-3 1999 To determine whether tacrolimus (FK506) similarly increases TGFbeta1 we have measured TGFbeta levels in blood samples from liver graft recipients who were of known TGFbeta1-responder status. Tacrolimus 33-38 transforming growth factor beta 1 Homo sapiens 60-67 10071036-0 1999 Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Tacrolimus 0-10 transforming growth factor beta 1 Homo sapiens 43-75 10071036-2 1999 In view of similarities between tacrolimus and CsA with respect to immunosuppressive mechanisms, we determined whether tacrolimus, in a fashion similar to CsA, induces TGF-beta1 hyperexpression in mammalian cells. Tacrolimus 119-129 transforming growth factor beta 1 Homo sapiens 168-177 9665007-0 1998 Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. Tacrolimus 42-52 transforming growth factor beta 1 Homo sapiens 74-82 9665007-3 1998 We investigated the effect of tacrolimus and CsA in tissue culture and found that there was indeed a negative effect on human lung small airway epithelial cell proliferation by recombinant transforming growth factor-beta (TGF-beta), which was reversed by anti-TGF-beta. Tacrolimus 30-40 transforming growth factor beta 1 Homo sapiens 189-220 9665007-3 1998 We investigated the effect of tacrolimus and CsA in tissue culture and found that there was indeed a negative effect on human lung small airway epithelial cell proliferation by recombinant transforming growth factor-beta (TGF-beta), which was reversed by anti-TGF-beta. Tacrolimus 30-40 transforming growth factor beta 1 Homo sapiens 222-230 9422408-2 1997 Recently, calcineurin phosphatase inhibition by cyclosporine or tacrolimus has been postulated to lead to diastolic hypertension through the induction of transforming growth factor-beta (TGF-beta) and resultant endothelin-mediated renal arteriolar vasospasm. Tacrolimus 64-74 transforming growth factor beta 1 Homo sapiens 154-185 9422408-2 1997 Recently, calcineurin phosphatase inhibition by cyclosporine or tacrolimus has been postulated to lead to diastolic hypertension through the induction of transforming growth factor-beta (TGF-beta) and resultant endothelin-mediated renal arteriolar vasospasm. Tacrolimus 64-74 transforming growth factor beta 1 Homo sapiens 187-195 7545487-3 1995 In contrast, both CsA and FK506 enhanced transforming growth factor beta (TGF beta) and IL-1 beta mRNA expression. Tacrolimus 26-31 transforming growth factor beta 1 Homo sapiens 74-82 1380951-3 1992 While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta). Tacrolimus 46-52 transforming growth factor beta 1 Homo sapiens 185-193 1380951-3 1992 While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta). Tacrolimus 46-52 transforming growth factor beta 1 Homo sapiens 245-253